Lexeo Therapeutics, Inc.
Business
Lexeo Therapeutics is a clinical-stage genetic medicine company developing AAV-based gene therapies to treat cardiovascular and neurodegenerative diseases caused by genetic mutations. The company's lead programs include LX2006 for Friedreich ataxia cardiomyopathy (Phase 1/2), LX2020 for PKP2-associated arrhythmogenic cardiomyopathy (Phase 1/2), LX2021 for Desmoplakin cardiomyopathy (preclinical), and LX2022 for TNNI3-related hypertrophic cardiomyopathy (preclinical), plus earlier-stage programs targeting APOE4-associated Alzheimer's disease. Lexeo retains exclusive worldwide development and commercialization rights to all product candidates and manufactures vectors using a proprietary Sf9-baculovirus production process.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development expenses | 64 | 74 | 53 | 49 | |
| General and administrative | 45 | 32 | 15 | 12 | |
| Total operating expenses | 109 | 106 | 69 | 61 | |
| Operating loss | −109 | −106 | −69 | −61 | |
| Gain on long-term investment | 3 | 0 | — | — | |
| Other expense, net | −18,000 | −9,000 | −13,000 | −2,000 | |
| Interest expense | −95,000 | −137,000 | −205,000 | — | |
| Interest income | 6 | 8 | 3 | 1 | |
| (Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net | −111,000 | 23,000 | — | — | |
| Total other income and expense | 9 | 7 | 2 | 1 | |
| Loss from operations before income taxes | −100 | −98 | — | — | |
| Income taxes | 0 | 0 | — | — | |
| Net loss | −100 | −98 | −66 | −59 | |
| Net unrealized gain (loss) on investments | 291,000 | −103,000 | — | — | |
| Total other comprehensive gain (loss) | 291,000 | −103,000 | — | — | |
| Comprehensive loss | −100 | −98 | −66 | — | |
| Net loss per common share, basic | −1.86 | −3.09 | −12.4 | −36.36 | |
| Net loss per common share, diluted | −1.86 | −3.09 | −12.4 | −36.36 | |
| Weighted average number of shares outstanding used in computation of net loss per common share, basic | 54 | 32 | 5 | 2 | |
| Weighted average number of shares outstanding used in computation of net loss per common share, diluted | 54 | 32 | 5 | 2 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 63 | 35 | 121 | 77 | 136 | |
| Current portion of investments in U.S. Treasury securities | 119 | 87 | — | — | — | |
| Prepaid expenses and other current assets | 7 | 5 | 3 | — | — | |
| Total current assets | 188 | 126 | 124 | 80 | — | |
| Non-current portion of investments in U.S. Treasury securities | 65 | 7 | — | — | — | |
| Long-term investment | 3 | 0 | — | — | — | |
| Restricted cash | 3 | 3 | 3 | 3 | — | |
| Property and equipment, net | 1 | 1 | 1 | 998,000 | — | |
| Lease right-of-use assets - finance | 1 | 1 | 2 | 2 | — | |
| Lease right-of-use assets - operating | 7 | 8 | 9 | 11 | — | |
| Total assets | 269 | 147 | 140 | 97 | — | |
| Accounts payable | 5 | 6 | 4 | 3 | — | |
| Accrued expenses and other current liabilities | 9 | 14 | 11 | 6 | — | |
| Current portion of lease liabilities - finance | 518,000 | 570,000 | 518,000 | 547,000 | — | |
| Current portion of lease liabilities - operating | 2 | 2 | 2 | 2 | — | |
| Total current liabilities | 17 | 23 | 17 | 14 | — | |
| Non-current portion of lease liabilities - finance | 327,000 | 817,000 | 1 | 2 | — | |
| Non-current portion of lease liabilities - operating | 5 | 6 | 8 | 9 | — | |
| Total liabilities | 22 | 30 | 26 | 25 | — | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of December 31, 2025; 73,001,766 shares issued and 73,001,350 shares outstanding as of December 31, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024 | 7,000 | 3,000 | 3,000 | 0 | — | |
| Treasury stock, at cost, 3,827 common shares as of December 31, 2025 and as of December 31, 2024 | −17,000 | −17,000 | — | — | — | |
| Additional paid-in capital | 627 | 397 | 295 | 2 | — | |
| Accumulated other comprehensive gain (loss) | 188,000 | −103,000 | — | — | — | |
| Accumulated deficit | −380 | −280 | −182 | −115 | — | |
| Total stockholders' equity | 247 | 117 | 114 | −113 | −56 | |
| Total liabilities and stockholders' equity | 269 | 147 | 140 | 97 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Reduction in the carrying amount of ROU assets, operating | 1 | 1 | 1 | 877,000 | |
| Reduction in the carrying amount of ROU assets, finance | 320,000 | 325,000 | 306,000 | 148,000 | |
| Stock based compensation expense | 12 | 12 | 3 | 2 | |
| Depreciation and amortization expense | 268,000 | 304,000 | 271,000 | 120,000 | |
| Non-cash gain on long-term investment | −3 | — | — | — | |
| Net realized gain on investments in U.S. Treasury securities | −17,000 | — | — | — | |
| Amortization of premium (accretion of discount) on investments in U.S. Treasury securities | 111,000 | −23,000 | — | — | |
| Prepaid expenses and other current assets | −2 | −2 | 990,000 | −2 | |
| Accounts payable | −2 | 2 | −180,000 | −426,000 | |
| Accrued expenses and other current liabilities | −4 | 3 | 2 | 4 | |
| Lease liabilities, operating | −1 | −1 | −1 | −298,000 | |
| Lease liabilities, finance | −9,000 | 10,000 | −5,000 | −6,000 | |
| Net cash used in operating activities | −99 | −81 | −59 | −55 | |
| Purchase of property and equipment | −397,000 | −481,000 | −115,000 | −672,000 | |
| Purchases of investments | −195 | −94 | — | — | |
| Proceeds from sales or maturities of investments | 106 | — | — | — | |
| Net cash used in investing activities | −90 | −94 | −165,000 | −901,000 | |
| Proceeds from exercise of stock options | 59,000 | 491,000 | 51,000 | 332,000 | |
| Payments on finance leases | −533,000 | −410,000 | −425,000 | −163,000 | |
| Treasury stock repurchases | — | −17,000 | — | — | |
| Proceeds from common stock issuances under 2023 ESPP | 270,000 | — | — | — | |
| Proceeds from issuance of common stock upon private placement offering, net of commissions and offering costs | — | 95 | — | — | |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement | 80 | — | 100 | — | |
| Proceeds from issuance of common stock and pre-funded warrants to purchase common stock upon October 2025 Financing Transactions | 154 | — | — | — | |
| Third-party commissions and offering costs incurred upon October 2025 Financing Transactions | −10 | — | — | — | |
| Net cash provided by financing activities | 217 | 89 | 104 | 189,000 | |
| Net change in cash, cash equivalents and restricted cash | 28 | −86 | 44 | −55 | |
| Interest paid | 104,000 | 127,000 | 176,000 | 77,000 | |
| Reclassification of internal use software into prepaid expenses | 18,000 | 98,000 | — | — | |
| (Property and equipment purchased in the prior period and paid in the current period), net of property and equipment purchased in the current period included in accounts payable | — | 120,000 | 141,000 | — | |
| Finance lease right-of use assets and finance lease liabilities recognized | — | 22,000 | — | 2 | |
| Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase, net of proceeds received from early exercise of unvested stock options subject to repurchase and recorded as deposit liabilities | 37,000 | 59,000 | 87,000 | −188,000 | |
| Unpaid offering costs included in accounts payable and accrued expenses | 25,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Lexeo Therapeutics, Inc.'s CIK number?
Lexeo Therapeutics, Inc.'s SEC CIK number is 0001907108 (1907108). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lexeo Therapeutics, Inc.'s SEC filings?
All of Lexeo Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Lexeo Therapeutics, Inc. last report earnings?
Lexeo Therapeutics, Inc. (LXEO) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-215674). This is Lexeo Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Lexeo Therapeutics, Inc.'s most recent earnings 8-K?
Lexeo Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-215674. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Lexeo Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →